SWHR Calls for Oversight on Clinical Laboratory Diagnostics

Published 5/9/18

Together with a committee of stakeholder organizations, SWHR sent a letter to congressional committee leadership urging Congress to reform the statutory oversight of clinical laboratory diagnostics, including laboratory developed tests (LDTs) and in vitro diagnostics (IVDs).

The coalition of patient advocates, providers, laboratories, and diagnostics manufacturers addressed the letter to Sen. Lamar Alexander (R-TN), Chairman of the Senate Health, Labor, Education, and Pension (HELP) Committee; Sen. Patty Murray (D-WA), Ranking Member of the Senate HELP Committee; Rep. Greg Walden (R-OR-02), Chair of the House Committee on Energy and Commerce; and Rep. Frank Pallone (D-NJ-06), Ranking Member of the House Committee on Energy and Commerce. Both committees have demonstrated dedicated leadership on the critical issue of clinical laboratory diagnostics through extensive stakeholder engagement. SWHR’s support of this letter indicates the organization’s vested interest in pushing Congress to continue to modernize laboratory diagnostic reform.